Biostatistics is necessary for all investigational drug or device development programmes to determine the efficacy and effectiveness in clinical trials. This includes the study designs, study conduct, determining the most effective data collection points and how analysis and reporting should be performed.
Quanticate’s biostatisticians have a desire for quality and implement the best approach to a client situation/scenario to ensure correct analysis without an over complex process. By using the appropriate tools, we are able to demonstrate the efficacy of a drug and present the results in the clearest way possible.
We are trusted by top pharmaceuticals as our personalised approach forms lasting relationships and enables our experts to transfer their biostatistics knowledge on to our customers.
Quanticate has been built around the expert knowledge and reputation across the industry of our statistical consultancy team over the past 25 years. Originally founded as a biostatistics contract research organisation (CRO), biostatistical services have always been a key component of Quanticate's services as part of our heritage.
Quanticate provides all levels of support from bespoke biostatistical consultancy for protocol design, calculation of sample sizes, power calculations, and/or the production of study randomization, through to study level analysis of Tables, Listings and Figures. We even provide support and advice for pre-clinical studies to ensure the study objective is being fulfilled.
Quanticate has experience across a wide range of therapeutic areas, all phases of research and development. Our scientific principles will guide you throughout your trial ensuring high quality data with your clinical trial reporting to support your regulatory submission.
Karen Ooms is responsible for overseeing the Statistics department at Quanticate. Karen is a Chartered Fellow of the Royal Statistical Society and has a background in biostatistics spanning over 25 years.